eXoZymes: A New Era in Sustainable Biomanufacturing

In the rapidly evolving landscape of biotechnology, a new player has emerged with a bold vision for sustainable and scalable biomanufacturing. Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems, has announced a corporate name change to eXoZymes, Inc. ("eXoZymes"), along with a new ticker symbol, "EXOZ," set to begin trading on the Nasdaq Capital Market on February 12, 2025. This rebranding marks a significant milestone for the company, as it seeks to establish itself as a pioneer in the field of exozymes, a new scientific concept introduced by the company to represent the missing last step for most synthetic biology (SynBio) projects: scaling on an industrial level.

eXoZymes' innovative platform leverages advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells. This approach enables the company to efficiently transform affordable and widely available feedstocks into a diverse range of valuable small-molecule chemicals, including active pharmaceutical ingredients, nutraceuticals, and biofuels. By freeing enzyme-driven chemical reactions from the limitations imposed by cellular environments, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the SynBio space, making exozymes the natural successor to most SynBio projects.

The company's rebranding to eXoZymes is a strategic move that brings clarity around its core technology and sets it apart from existing technologies. The new name, eXoZymes, is a scientific concept introduced by the company to represent the missing last step for most SynBio projects: scaling on an industrial level. This rebranding aligns with the company's mission to replace traditional chemical production methods with a sustainable and eco-friendly alternative, using advanced enzymes engineered with AI to thrive in a bioreactor outside of living cells.

The change in ticker symbol from IZTC to EXOZ is expected to have several effects on the company's trading dynamics and accessibility to investors. Firstly, the new ticker symbol is more reflective of the company's core technology and brand, which can help improve recognition and understanding among investors. As stated by CEO Michael Heltzen, "We believe that our technology is so fundamental and has so much potential that trying to label it with existing nomenclature falls short, which is why we’re introducing ‘exozymes’ as a scientific concept." This rebranding can help attract investors who are interested in the company's innovative approach to biomanufacturing.

Secondly, the new ticker symbol may make it easier for investors to find and track the company's stock. The previous ticker symbol, IZTC, was not as descriptive or memorable as EXOZ, which could have made it more difficult for investors to locate and monitor the company's performance. With the new ticker symbol, investors may find it easier to identify and engage with the company's stock.

Lastly, the change in ticker symbol may also impact the company's liquidity and trading volume. A more recognizable and descriptive ticker symbol can help attract more investors, potentially leading to increased trading volume and improved liquidity. This can make it easier for investors to buy and sell the company's stock, as well as provide a more accurate reflection of the company's market value.

In conclusion, the rebranding of Invizyne Technologies to eXoZymes Inc. is a strategic move that brings clarity around the company's core technology and sets it apart from existing technologies. The new name, eXoZymes, is a scientific concept introduced by the company to represent the missing last step for most SynBio projects: scaling on an industrial level. This rebranding aligns with the company's mission to replace traditional chemical production methods with a sustainable and eco-friendly alternative, using advanced enzymes engineered with AI to thrive in a bioreactor outside of living cells. The change in ticker symbol from IZTC to EXOZ is expected to have several effects on the company's trading dynamics and accessibility to investors, including improved brand recognition, easier stock identification, and potentially increased trading volume and liquidity. As eXoZymes continues to innovate and grow, investors should keep a close eye on this promising company in the biotechnology sector.